PURPOSE: Summarize current knowledge, critical gaps in knowledge, and recommendations to advance the field of metastatic bone cancer. EXPERIMENTAL DESIGN: A multidisciplinary consensus conference was convened to review recent progress in basic and clinical research, assess critical gaps in current knowledge, and prioritize recommendations to advance research in the next 5 years. The program addressed three principal topics: biology of metastasis, preserving normal bone health, and optimizing bone-targeted therapies. RESULTS: A variety of specific recommendations were identified as important to advance research and clinical care over the next 5 years. CONCLUSIONS: Priorities for research in bone biology include characterizing components of the stem cell niche in bone, developing oncogenic immunocompetent animal models of bone metastasis, and investigating the unique contribution of the bone microenvironment to tumor growth and dormancy. Priorities for research in preserving normal bone health include developing methods to measure and characterize disseminating tumor cells, assessing outcomes from the major prevention trials currently in progress, and improving methodologies to assess risks and benefits of treatment. Priorities for optimizing bone-targeted therapies include advancing studies of serum proteomics and genomics to reliably identify patients who will develop bone metastases, enhancing imaging for early detection of bone metastases and early response evaluation, and developing new tests to evaluate response to bone-directed treatments.
PURPOSE: Summarize current knowledge, critical gaps in knowledge, and recommendations to advance the field of metastatic bone cancer. EXPERIMENTAL DESIGN: A multidisciplinary consensus conference was convened to review recent progress in basic and clinical research, assess critical gaps in current knowledge, and prioritize recommendations to advance research in the next 5 years. The program addressed three principal topics: biology of metastasis, preserving normal bone health, and optimizing bone-targeted therapies. RESULTS: A variety of specific recommendations were identified as important to advance research and clinical care over the next 5 years. CONCLUSIONS: Priorities for research in bone biology include characterizing components of the stem cell niche in bone, developing oncogenic immunocompetent animal models of bone metastasis, and investigating the unique contribution of the bone microenvironment to tumor growth and dormancy. Priorities for research in preserving normal bone health include developing methods to measure and characterize disseminating tumor cells, assessing outcomes from the major prevention trials currently in progress, and improving methodologies to assess risks and benefits of treatment. Priorities for optimizing bone-targeted therapies include advancing studies of serum proteomics and genomics to reliably identify patients who will develop bone metastases, enhancing imaging for early detection of bone metastases and early response evaluation, and developing new tests to evaluate response to bone-directed treatments.
Authors: Nigel J Bundred; Ian D Campbell; Neville Davidson; Richard H DeBoer; Holger Eidtmann; Alain Monnier; Patrick Neven; Gunter von Minckwitz; Joel C Miller; Nora L Schenk; Robert E Coleman Journal: Cancer Date: 2008-03-01 Impact factor: 6.860
Authors: Penelope D Ottewell; Hannu Mönkkönen; Mark Jones; Diane V Lefley; Robert E Coleman; Ingunn Holen Journal: J Natl Cancer Inst Date: 2008-08-11 Impact factor: 13.506
Authors: Claire M Edwards; James R Edwards; Seint T Lwin; Javier Esparza; Babatunde O Oyajobi; Brandon McCluskey; Steven Munoz; Barry Grubbs; Gregory R Mundy Journal: Blood Date: 2007-12-19 Impact factor: 22.113
Authors: P Hadji; J-J Body; M S Aapro; A Brufsky; R E Coleman; T Guise; A Lipton; M Tubiana-Hulin Journal: Ann Oncol Date: 2008-04-29 Impact factor: 32.976
Authors: R Scott Pearsall; Ernesto Canalis; Milton Cornwall-Brady; Kathryn W Underwood; Brendan Haigis; Jeffrey Ucran; Ravindra Kumar; Eileen Pobre; Asya Grinberg; Eric D Werner; Vaida Glatt; Lisa Stadmeyer; Deanna Smith; Jasbir Seehra; Mary L Bouxsein Journal: Proc Natl Acad Sci U S A Date: 2008-05-06 Impact factor: 11.205
Authors: Qian Zhang; Yan Lu; Steven T Proulx; Ruolin Guo; Zhenqiang Yao; Edward M Schwarz; Brendan F Boyce; Lianping Xing Journal: Arthritis Res Ther Date: 2007 Impact factor: 5.156
Authors: Hai Wang; Cuijuan Yu; Xia Gao; Thomas Welte; Aaron M Muscarella; Lin Tian; Hong Zhao; Zhen Zhao; Shiyu Du; Jianning Tao; Brendan Lee; Thomas F Westbrook; Stephen T C Wong; Xin Jin; Jeffrey M Rosen; C Kent Osborne; Xiang H-F Zhang Journal: Cancer Cell Date: 2015-01-15 Impact factor: 31.743
Authors: Younghun Jung; Yusuke Shiozawa; Jianhua Wang; Jingcheng Wang; Zhuo Wang; Elisabeth A Pedersen; Clara H Lee; Christopher L Hall; Phillip J Hogg; Paul H Krebsbach; Evan T Keller; Russell S Taichman Journal: Mol Cancer Res Date: 2009-10-13 Impact factor: 5.852
Authors: Kaitlin Koo; Kinsey Lam; Nicole Mittmann; Andre Konski; Kristopher Dennis; Liang Zeng; Henry Lam; Edward Chow Journal: Support Care Cancer Date: 2013-03-22 Impact factor: 3.603